Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a clinical-stage biopharmaceutical company that discovers and develops RNA interference-based therapies. Revenue comes primarily from collaboration agreements, licensing arrangements, and milestone payments with pharmaceutical partners, as the company had not achieved commercial product sales as of its FY2024 10-K filing, though it entered commercial launch of REDEMPIO in 2025 per its FY2025 10-K filed November 25, 2025. The company competes against large pharmaceutical companies, small biotech firms, private companies, and research institutions, as disclosed in its FY2025 10-K. Arrowhead maintains research facilities through lease agreements with University Research Park and office space in Pasadena, California. The balance sheet carries an accumulated deficit as of September 30, 2025, reflecting the capital-intensive nature of drug development prior to meaningful commercial revenue. Manufacturing for commercial products is outsourced to third-party contract manufacturers.

Revenue model

Collaboration and licensing agreements generating upfront payments, milestones, and royalties. The company had not achieved commercial drug sales as of its prior filings, with REDEMPIO entering commercial launch in 2025 (per the FY2025 10-K filed November 25, 2025). Revenue is recognized under FASB Topic 606.

Products and services

RNA interference (RNAi) therapeutic candidates across multiple disease areas. REDEMPIO entered commercial launch in 2025 per the FY2025 10-K. Drug substance and drug product manufacturing for REDEMPIO is handled by third-party manufacturers under contract.

Customers and end markets

Pharmaceutical and biotech collaboration partners as primary revenue counterparties. End markets include patients with diseases addressable by RNAi therapeutics. Pricing and reimbursement exposure in the United States and EU member states, where HTA processes in countries including France, Germany, Ireland, Italy, and Sweden influence market access.

Value-chain role

Drug discoverer and developer. Relies on contract research organizations for clinical trial execution and third-party contract manufacturers for drug substance and drug product. Does not operate its own commercial-scale manufacturing.

Geographic exposure

Headquartered in the United States. Operations include research facilities in Madison, Wisconsin (University Research Park leases) and office space in Pasadena, California. Regulatory and reimbursement exposure in the EU across multiple member states.

Competitors

Large pharmaceutical companies, Small biotech companies, Private companies, Research institutions

Source: SEC 10-K, filed 2025-11-25

Industry: Pharmaceutical Preparations Peers: ACADIA Pharmaceuticals Inc AMICUS THERAPEUTICS, INC. Beam Therapeutics Inc ChemoCentryx, Inc. Denali Therapeutics Inc Insmed Inc Mirati Therapeutics, Inc. PTC Therapeutics Inc Ultragenyx Pharmaceutical Inc